Patient preferences for treatment of lupus nephritis

Arthritis Care and Research

Volumn 47, Issue 4, 2002, Pages 421-428

  Fraenkel, Liana ^a,b,c   Bogardus, Sidney ^a   Concato, John ^a,b  

^a YALE UNIVERSITY   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lupus nephritis; Patient preferences; Toxicity

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; SURVIVAL;

EID: 0037103154     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10534     Document Type: Article

References (35)

1. Treatment of lupus nephritis
2. NIH conference: Lupus nephritis
3. Management of lupus nephritis
4. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: Results of a pooled analysis
5. Approach to lupus nephritis based upon randomized trials
6. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
7. Speech and survival: Tradeoffs between quality and quantity of life in laryngeal cancer
8. Fallacy of the five year survival in lung cancer
9. Patient preferences: Survival vs quality of life considerations
10. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer
11. Estrogen use in postmenopausal women: Costs, risks, and benefits
12. Women's and physicians' utilities for health outcomes in estrogen replacement therapy
13. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation
14. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer
15. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
16. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study
17. Side-effects of intravenous cyclophosphamide pulse therapy
18. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow-up study
19. SAARDs-II
20. Immune suppressive medications: Their benefits and side effects
21. Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice
22. The effect of patients' preferences on racial differences in access to renal transplantation
23. Measuring patients' desire for autonomy: Decision making and information seeking preferences among medical patients
24. Decision making during serious illness: What role do patients really want to play?
25. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia
26. Patient preferences for management of localized prostate cancer
27. On the elicitation of preferences for alternative therapies
28. Impact of patient preferences on the selection of therapy
29. Assessment of the time trade-off values for prophylactic mastectomy of women with genetic predisposition to breast cancer
30. Patient preferences for interferon alfa in multiple myeloma
31. Information and participation preferences among cancer patients
32. Expanding patient involvement in care: Effects on patient outcomes
33. Measuring consumer desire for participation in clinical decision making
34. What questions do patients with curable prostate cancer want answered?